Organicell Begins Up-Listing Process On NASDAQ Exchange


MIAMI–()–Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it is currently exploring options to up-list its common stock to the NASDAQ Capital Market tier of the NASDAQ Stock Market, LLC.

To qualify and be approved for such up-listing, the Company would be required to meet all financial, share price and corporate governance listing requirements of NASDAQ, which for the NASDAQ Capital Market includes a minimum of $5 million in shareholder equity and a minimum trading price of $4.00 per share. In order to meet these criteria, the Company would likely need to raise additional capital in…



Click here to view the original article.

S&P/ASX 200 
7,052.60  38.40  0.55%  
ALL ORDINARIES 
7,284.10  44.70  0.62%  
Dow Jones Industrial Average 
34,382.13  360.73  1.06%  
S&P 500 
4,173.85  61.35  1.49%  
NASDAQ Composite 
13,429.98  304.98  2.32%  
NYSE COMPOSITE (DJ) 
16,415.36  233.76  1.44%  
FTSE 100 
7,043.61  80.28  1.15%  
DAX PERFORMANCE-INDEX 
15,416.64  216.94  1.43%  
Nikkei 225 
28,065.90  18.57  0.07%  
HANG SENG INDEX 
28,027.57  308.87  1.11%